Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT07476287

Public ClinicalTrials.gov record NCT07476287. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working. To join the study, participants must meet the following conditions: * Are aged 18 years or older * Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted) * Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs) * Have healthy organs based on medical tests and are in good physical condition After joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.

Study identification

NCT ID: NCT07476287
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Pfizer; Industry
Enrollment: 40 participants

Conditions and interventions

Conditions

Interventions

PF-08634404 Drug
Chemotherapy Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2, 2026 (Actual)
Primary completion: Mar 24, 2028 (Estimated)
Completion: Mar 24, 2031 (Estimated)
Last update posted: Oct 9, 2026

2026 – 2031

United States locations

U.S. sites: 23
U.S. states: 4
U.S. cities: 16

Facility	City	State	ZIP	Site status
City of Hope National Medical Center	Duarte	California	91010	Recruiting
UC San Diego Medical Center - Encinitas	Encinitas	California	92024	Recruiting
City of Hope Lennar Foundation Cancer Center	Irvine	California	92618	Recruiting
UC San Diego Koman Family Outpatient Pavilion	La Jolla	California	92037	Recruiting
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)	La Jolla	California	92037	Recruiting
UC San Diego Moores Cancer Center	La Jolla	California	92037	Recruiting
UC San Diego Sulpizio Cardiovascular Center	La Jolla	California	92037	Recruiting
UC San Diego Medical Center - Bankers Hill	San Diego	California	92101	Recruiting
UC San Diego McGrath Outpatient Pavilion - Hillcrest	San Diego	California	92103	Recruiting
UC San Diego Medical Center- Hillcrest	San Diego	California	92103	Recruiting
UC San Diego Medical Center - Rancho Bernardo	San Diego	California	92127	Recruiting
UC San Diego Medical Center - Vista	Vista	California	92081	Recruiting
Hope and Healing Clinical Research	Hinsdale	Illinois	60521	Recruiting
Hope and Healing Clinical Research	New Lenox	Illinois	60451	Recruiting
MSK Basking Ridge	Basking Ridge	New Jersey	07920	Recruiting
MSK Monmouth	Middletown	New Jersey	07748	Recruiting
MSK Bergen.	Montvale	New Jersey	07645	Recruiting
MSK Commack	Commack	New York	11725	Recruiting
MSK Westchester	Harrison	New York	10604	Recruiting
Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy	Long Island City	New York	11101	Recruiting
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).	New York	New York	10021	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
MSK Nassau	Uniondale	New York	11553	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07476287, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 9, 2026 · Synced Oct 30, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07476287 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →